Details for Patent: 9,610,260

Which drugs does patent 9,610,260 protect, and when does it expire?

Patent 9,610,260 protects FINTEPLA and is included in one NDA.

Protection for FINTEPLA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-nine patent family members in sixteen countries.

Summary for Patent: 9,610,260

Title:	Method for the treatment of Dravet Syndrome
Abstract:	A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.
Inventor(s):	Berten Ceulemens, Lieven Lagae
Assignee:	UNIVERSITY HOSPITAL ANTWERP , Katholieke Universiteit Leuven
Application Number:	US14/447,253
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,610,260
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 9,610,260

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ucb Inc	FINTEPLA	fenfluramine hydrochloride	SOLUTION;ORAL	212102-001	Jun 25, 2020		RX	Yes	Yes	9,610,260*PED				Y

International Family Members for US Patent 9,610,260

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014261329
Australia	2019203448
Australia	2019203832
Australia	2020267264
Brazil	112015027282
Canada	2909335